May 18 Janssen Research & Development LLC: * Janssen to present data from six compounds including Daratumumab and Ibrutinib at the 2016 American Society of Clinical Oncology (ASCO) annual meeting Source text for Eikon: Further company coverage: ... Reuters UK, 1 week ago
Pfizer says will present data on 6 drugs at ASCO meeting - Yahoo! Finance, 1 week ago
Janssen to Present Data from Six Compounds Including Daratumumab and Ibrutinib at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting - WorldNetDaily, 1 week ago
U.S. FDA Expands IMBRUVICA ibrutinib Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia CLL and New...
U.S. FDA Expands IMBRUVICA ibrutinib Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia CLL and New Indication for Small Lymphocytic Lymphoma SLL Patients By a News Reporter-Staff News Editor at Biotech ...Pharmacy Choice, 4 days ago Growth Kinetics May Help Identify Ibrutinib Resistance in CLL Patients OncoTherapy Network, 4 days ago FDA Updates Ibrutinib Labeling to Include Survival Data ASH Clinical News, 1 week ago Extended RESONATE Data Illuminates Ibrutinib's Benefits in High-Risk CLL Targeted Oncology, 1 week ago
Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion, recommending broadening the existing marketing authorisation for ibrutinib ...Global Hospital & Healthcare Management, 2 weeks ago European CHMP Recommends Approval for Front-line Use of Ibrutinib for CLL ASH Clinical News, 2 weeks ago Janssen/AbbVie's Imbruvica boosted by US label update pharmaphorum, 2 weeks ago Ibrutinib receives positive CHMP opinion for expanded use in previously untreated CLL patients Ecancer Medicalscience, 3 weeks ago
TORONTO, ON Janssen Inc. reports that Health Canada has issued a Notice of Compliance (NOC) for IMBRUVICA® (ibrutinib), for the treatment of patients with Waldenström's macroglobulinemia (WM). WM is a rare, incurable type of non-Hodgkin ...BiotechnologyFocus.ca, 1 week ago Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenström's Macroglobulinemia FirstWord Pharma, 2 weeks ago Ibrutinib and Waldenstroms Macroglobulin... Oncology Tube, 1 month ago How to decide between Ibrutinib and Idel... Oncology Tube, 1 month ago
Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology
-Studies demonstrate potential mechanistic synergies with the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, as well as with immunomodulation- BOSTON--(EON: Enhanced Online News Overall these data further support the broad versatility and ...EON: Enhanced Online News, 1 month ago Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology BioSpace, 1 month ago
0 Flares 0 Flares × FROM ASCO 2016 Venetoclax monotherapy was active, and even elicited minimal residual disease negativity in a proportion of patients with chronic lymphocytic leukemia (CLL) that was resistant or refractory to ibrutinib or ...PM 360, 2 days ago
Abstract: Ibrutinib with Low-Dose Dexamethasone in Relapsed or Relapsed and RefractoryOncology Tube, 4 days ago
A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/A... A continuing education program is offered as a supplement to this webcast at the following location: ...Oncology Tube, 6 days ago
imedex has 822 videos Subscribe Here Loading........ Video URL : Embed : Description: In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete ...Oncology Tube, 1 week ago
Description: An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that worsened despite prior therapy. At a ...Oncology Tube, 1 week ago Ibrutinib Plus Bendamustine and Rituximab Yields Positive Results for Patients With CLL/SLL ASH Clinical News, 1 month ago Bendamustine + Rituximab Effective for Untreated CLL in 'Real-life' Study Cancer Therapy Advisor, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!